YOUR SEARCH FOR Text 257 RESULTS
241 of Total
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with
242 of Total
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Offi
245 of Total
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the Eu
246 of Total
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Canc